FULL LIST

  • Dr. Josephine Wu’s OPTO-BIOPRINTING Project

    Dr. Josephine Wu’s OPTO-BIOPRINTING Project

    Dr. Josephine Wu, a researcher at Trinity College Dublin, is making noise in the field of tissue engineering with her innovative project, OPTO-BIOPRINTING. Supported by an €800,000 Wellcome Early Career Award, Dr. Wu aims to develop a novel approach to creating living tissues. OPTO-BIOPRINTING seeks to overcome current challenges in tissue engineering by leveraging the…

  • Carcinotech’s 3D-Printed Tumor Models: A New Possibility in Cancer Research

    Carcinotech’s 3D-Printed Tumor Models: A New Possibility in Cancer Research

    Carcinotech’s recent study introduces a potential approach in cancer research through the development of patient-derived, 3D-printed lung cancer models. Their method, showcased at the 2024 European Association for Cancer Research Annual Congress and published in Molecular Oncology, replicates the tumor microenvironment (TME) using cells from patient biopsies, including TME components like cancer stem cells, CAFs,…

  • Brinter’s 3D Bioprinter Set to Board the International Space Station

    Brinter’s 3D Bioprinter Set to Board the International Space Station

    The intersection of bioprinting and space exploration is reaching a new milestone as Finnish bioprinting firm, Brinter AM Technologies Oy, prepares to launch its Brinter Core 3D bioprinter to the International Space Station (ISS). This project, in collaboration with Redwire Space NV and funded by the European Space Agency (ESA), will see the Brinter Core…

  • CollPlant and Stratasys Initiate Pre-Clinical Study for Regenerative Breast Implants

    CollPlant and Stratasys Initiate Pre-Clinical Study for Regenerative Breast Implants

    In a new development for bioprinting, CollPlant Biotechnologies and Stratasys Ltd. have launched a pre-clinical study focused on the viability of 3D-printed, regenerative breast implants. This collaboration marks a significant stride in the $3 billion breast implant market, introducing a novel approach that could redefine both reconstructive and aesthetic procedures. The Innovation Behind the Implants…

  • Co-Axial SWIFT – Embedding Biomimetic Vascular Networks with Co-axial Sacrificial Writing into Functional Tissue Introduction

    Co-Axial SWIFT – Embedding Biomimetic Vascular Networks with Co-axial Sacrificial Writing into Functional Tissue Introduction

    Introduction Bioprinting human tissues and organs that include biomimetic vascular networks is becoming increasingly essential in the field of regenerative medicine. The major challenge lies in creating perfusable channels within cellular and acellular matrices that mirror the complex structures of native blood vessels. A recent study by Stankey et al., published in Advanced Materials, introduces…

  • WFIRM publishes Science Translation Paper on Full-Thickness Bioprinted Skin

    WFIRM publishes Science Translation Paper on Full-Thickness Bioprinted Skin

    New milestone reached in bioprinting with the successful creation of full-thickness human skin, as detailed in a recent study published in Science Translational Medicine. Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have developed a bioprinted skin graft that mimics the complexity and functionality of natural human skin, offering new hope for improved…

  • Redwire to Test 3D Bioprinted Liver Tissue in Space, Reinforcing the Company’s Focus on Transforming the Future of Organ Transplantation on Earth

    Redwire to Test 3D Bioprinted Liver Tissue in Space, Reinforcing the Company’s Focus on Transforming the Future of Organ Transplantation on Earth

    JACKSONVILLE, Fla. (July 30, 2024) – Redwire Corporation (NYSE: RDW), a leading innovator in space infrastructure, announced a pioneering experiment set for launch to the International Space Station (ISS). This mission aims to study the effects of microgravity on tissue bioprinting and culturing, in collaboration with the Wake Forest Institute of Regenerative Medicine (WFIRM). Redwire…

  • ARPA-H Launches Groundbreaking Program to Push Further Bioprinting Therapies on Demand

    ARPA-H Launches Groundbreaking Program to Push Further Bioprinting Therapies on Demand

    Addressing the Organ Shortage Crisis The Advanced Research Projects Agency for Health (ARPA-H), a part of the U.S. Department of Health and Human Services (HHS), has announced the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program. This ambitious initiative aims to help push forward organ transplantation by leveraging cutting-edge bioprinting technology and regenerative medicine to potentially…

  • Aspect Biosystems receives Canadian Government funding to establish biomanufacturing center for bioprinted therapies

    Aspect Biosystems receives Canadian Government funding to establish biomanufacturing center for bioprinted therapies

    Vancouver, BC, Canada – July 10, 2024 – Aspect Biosystems, a biotech company which has chosen to focus on bioprinting tissue therapeutics, has secured a $72.75 million investment from the Canadian and British Columbian governments. This funding is a significant contribution to a $200 million, multi-year initiative aimed at enhancing Aspect’s clinical biomanufacturing capabilities, comprehensive…

Subscribe

Enter your email below to receive updates.